Rafferty Asset Management, LLC Bio Atla, Inc. Transaction History

Rafferty Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $363,881 - $1.56 Million	-83,078 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$19.0 - $30.95 $822,168 - $1.34 Million	43,272 Added 108.71%	83,078 $1.63 Million
Q3 2021 Nov 10, 2021	BUY	$29.44 - $43.74 $422,405 - $627,581	14,348 Added 56.36%	39,806 $1.17 Million
Q2 2021 Aug 10, 2021	BUY	$38.07 - $56.17 $969,186 - $1.43 Million	25,458 New	25,458 $1.08 Million

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.